Vancomycin AUC-Guided Dosing
ورودیهای بالینی بیمار
حداقل ۲۰ — حداکثر ۳۰۰ • واحد: kg
حداقل ۲۵۰ — حداکثر ۴۰۰۰ • واحد: mg
حداقل ۶ — حداکثر ۷۲ • واحد: hours
حداقل ۱ — حداکثر ۱۰۰ • واحد: mg/L
حداقل ۰ — حداکثر ۷۲ • واحد: hours
حداقل ۱ — حداکثر ۱۰۰ • واحد: mg/L
حداقل ۰ — حداکثر ۷۲ • واحد: hours
حداقل ۰.۱۲۵ — حداکثر ۸ • واحد: mg/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Below target0–399.9
- In target400–600
- Above target600.1–10000
The Vancomycin AUC-Guided Dosing calculates calculating standardized physiological indices and stratifying general clinical risk. Key inputs include weight kg. Scores guide individualizing bedside clinical management, scheduling routine follow-up, and monitoring clinical progress. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
AUC-guided vancomycin dosing check via the two-concentration method: elimination rate constant Ke from two timed levels, clearance from Ke × Vd (0.7 L/kg), then AUC24 = total daily dose / clearance. Target AUC24 400-600 mg·h/L (AUC/MIC 400-600) per the 2020 vancomycin guidelines.
Clinical Indication
The Vancomycin AUC-Guided Dosing is indicated for bedside clinical practice to support AUC-guided vancomycin dosing check via the two-concentration method: elimination rate constant Ke from two timed levels, clearance from Ke × Vd (0.7 L/kg), then AUC24 = total daily dose / clearance. Target AUC24 400-600 mg·h/L (AUC/MIC 400-600) per the 2020 vancomycin guidelines.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult ambulatory and hospitalized patient cohorts evaluated for systemic illness, physiologic risk, or diagnostic probability. Clinical application is indicated across General medical-surgical inpatient units, primary care clinics, and ambulatory outpatient facilities.
Limitations & Contraindications
Single-point score values can obscure rapid temporal clinical deterioration; serial clinical reassessment is essential.
Clinical Pearls & Action Plan
Calculated indices must be contextualized alongside complete clinical history, physical exam, and dynamic trajectory.
Ke = ln(C1/C2)/(t2-t1); CL = Ke * 0.7 * weight_kg; AUC24 = (dose_mg * 24/interval_h) / CL
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| weight_kg | float | Yes | Body weight(kg) |
| dose_mg | float | Yes | Vancomycin dose per administration(mg) |
| interval_h | float | Yes | Dosing interval(hours) |
| level1 | float | Yes | First measured concentration (earlier)(mg/L) |
| time1_h | float | Yes | Time of first level (hours after start of infusion)(hours) |
| level2 | float | Yes | Second measured concentration (later, lower)(mg/L) |
| time2_h | float | Yes | Time of second level (hours after start of infusion)(hours) |
| mic | float | Yes | Pathogen MIC(mg/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–399.9 | Below target | AUC below target |
| 400–600 | In target | AUC in target range |
| 600.1–10000 | Above target | AUC above target |
Evidence-Based References (EBM)
- Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2020;77(11):835-864. (AUC/MIC 400-600 target)